Stock Market News3 weeks MCK Stock Before Q3 Earnings: A Smart Buy or Risky Investment? Zacks
McKesson’s third-quarter fiscal 2025 results are likely to reflect the solid display by the U.S. Pharmaceutical and Specialty Solutions segment, driven by higher prescription volume.
X